Figures & data
Figure 1 Competitive phosphate binding of sevelamer carbonate and Genz-644470 in vitro.
Figure 2 CONSORT diagram of patient disposition, all randomized patients.
Table 1 Patient demographics and renal history, safety set
Figure 3 Mean (± standard deviation) change in serum phosphorus from baseline to end of treatment (day 22).
Figure 4 Changes from baseline in serum phosphorus at each visit following treatment with Genz-644470 (A) and sevelamer (B).
Table 2 Low-density lipoprotein cholesterol (mg/dL) change from baseline to day 22 (end of treatment)
Table 3 Change from baseline to day 22 (end of treatment) in corrected serum calcium and intact parathyroid hormone
Table 4 Treatment-related adverse events occurring in three or more patients
Table S1 Principal investigators and participating sites